42results about How to "Suitable for routine determination" patented technology

The invention discloses a method for determining the concentration of tadalafil in blood plasma by liquid chromatography-mass spectrometry, which adopts a liquid chromatography-mass spectrometry system for determination and comprises the following steps: taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction and pretreatment, performing separating by usinga chromatographic column, and performing detecting by using a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the blood concentration of tadalafil; according to the method, the linear range of a plasma standard curve is 1-600ng / mL, the intra-batch precision RSD and theinter-batch precision RSD are both less than + / -15%, and the method is suitable for measuring the concentration of tadalafil in plasma.

The invention discloses a method for determining concentration of carbamazepine in plasma by liquid chromatography mass spectrometry. A liquid chromatography mass spectrometry system is used for determining. A sample to be determined is added with a certain amount of mixed organic solvent to extract twice, is separated through a chromatographic column after pretreatment, and is detected by a massspectrometer. The method is rapid, accurate, high in sensitivity, and simple and convenient to operate. The method provides a basis for the blood drug concentration determination of carbamazepine. Thelinear range of a plasma standard curve in the method is 5 to 1000 ng / mL. The intra-batch and inter-batch precision RSD are less than + / -15%. The method is suitable for determining the concentrationof carbamazepine in the plasma.

The invention discloses a met / hod for determining the concentration of 5'-methoxyl-3',4'-methylenedioxyphenyl cinnamic acid isobutyl amide in plasma. A liquid chromatography-mass system is adopted to determine. The method comprises the following steps: taking a to-be-determined sample first, adding a certain quantity of organic solvent for extraction, separating through a chromatographic column after pretreatment, and determining by using a mass spectrometry detector. The method disclosed by the invention has the advantages of rapidity, accuracy, high sensitivity, simplicity and convenience in operation and is suitable for determining the concentration of 5'-methoxyl-3',4'-methylenedioxyphenyl cinnamic acid isobutyl amide in plasma.

The invention discloses a method for measuring concentration of 5,2'-dyhydroxyl,6,7,8,5'-tetramethoxyflavone (skullcapflavone II) in plasma. A liquid chromatography-mass spectrometry system is used for carrying out measuring, a sample to be measured is firstly taken, a certain amount of organic solvent is added for medicine liquid-liquid extraction, after pretreatment, chromatographic column separation is carried out, and a mass spectrometry detector is used for carrying out detection. According to the method, quickness and accuracy are achieved, sensitivity is high, and operation is easy and convenient; the method is suitable for measuring the concentration of skullcapflavone II in the plasma.

The invention discloses a method for detecting chaetoglobosin concentration in blood plasma. The method adopts a liquid chromatography tandem mass spectrometry system to perform detection, a sample to be detected is firstly taken, a certain amount of organic menstruum protein precipitant is added to perform protein precipitation, and detection is performed through chromatographic column separation and a mass spectrum detector after pretreatment. The method is quick, accurate, high in sensitivity, simple and convenient to operate and suitable for concentration detection in the blood plasma.

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to an analysis method for determining dimethyl sulfate in pyraclostrobin by a gas chromatography-mass spectrometry method. The invention discloses an analysis method for measuring dimethyl sulfate in pyraclostrobin by gas chromatography-mass spectrometry. The analysis method comprises the following steps: (1) preparing a standard solution; (2) drawing a standard curve; and (3) determining the content of dimethyl sulfate in the sample. Compared with the prior art, the method disclosed by the invention has the advantages of simplicity and convenience in sample preparation, small sample dosage and suitability for conventional determination; the sensitivity is high, and the lowest detection limit of dimethyl sulfate is 0.20 mg / kg. The method is simple in test process, high in sensitivity and good in accuracy.

The invention discloses a method for determining the concentration of omeprazole in plasma by liquid chromatography-mass spectrometry. The method adopts a liquid chromatography-mass spectrometry system for determination and comprises the steps of firstly taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction and pretreatment, separating by a chromatographic column, and detecting by a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the blood concentration of omeprazole; the linear range of a plasma standard curve of the method is 2 to 1500ng / mL, the intra-batch and inter-batch precision RSD is less than + / -15%, and the method is suitable for determining the concentration of omeprazole in plasma.

The invention provides a method for determining the concentration of hydrochlorothiazide, losartan and active hydroxy acid metabolite 5-carboxylic acid losartan in plasma by liquid chromatography-massspectrometry. The method comprises the following steps of: (1) pretreating a plasma sample; (2) detecting by liquid chromatography-mass spectrometry; (3) preparing a standard curve; and (4) determining the concentration of hydrochlorothiazide, losartan and active hydroxy acid metabolite 5-carboxylic acid losartan in plasma. The method provided by the invention is rapid, accurate, high in sensitivity and simple to operate, and serves clinical application of medicines.

The invention discloses a method for determining the concentration of lacosamide in blood plasma by liquid chromatography-mass spectrometry, which adopts a liquid chromatography-mass spectrometry system for determination, and comprises the following steps: taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction and pretreatment, separating by a chromatographic column, and detecting by a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for determining the blood concentration of lacosamide; and according to the method, the linear range of the plasma standard curve is 100-15000 ng / mL, the intra-batch precision RSD and the inter-batch precision RSD are both smaller than + / -15%, and the method is suitable for measuring the concentration of lacosamide in plasma.

The invention discloses a method for measuring the concentration of terazosin in plasma by liquid chromatography-mass spectrometry. The method adopts a liquid chromatography-mass spectrometry system for determination, and comprises the following steps: firstly taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction and pretreatment, separating by a chromatographic column, and detecting by a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for determining the plasma concentration of terazosin; and the linear range of a plasma standard curve of the method is 1-200 ng / mL, the intra-batch and inter-batch precision RSD is less than + / -15%, and the method is suitable for measuring the concentration of terazosin in plasma.

The invention discloses a method for determining the concentration of cetirizine in blood plasma by liquid chromatography-mass spectrometry, which adopts a liquid chromatography-mass spectrometry system for determination, and comprises the following steps: taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction and pretreatment, performing separating by using a chromatographic column, and performing detecting by using a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the blood concentration of cetirizine; according to the method, the linear range of the plasma standard curve is 1-600ng / mL, the intra-batch precision RSD and the inter-batch precision RSD are both less than + / -15%, and the method is suitable for measuring the concentration of cetirizine in plasma.

The invention discloses a method for determining the concentration of glimepiride in blood plasma by liquid chromatography-mass spectrometry, which adopts a liquid chromatography-mass spectrometry system for determination and comprises the following steps: taking a sample to be determined, adding a certain amount of mixed organic solvent for extraction and pretreatment, performing separating by achromatographic column, and performing detecting by using a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the blood concentration of glimepiride; the linear range of a plasma standard curve of the method is 0.5-500 ng / mL, the intra-batch precision RSD and the inter-batch precision RSD are both smaller than + / -15%, and the method is suitable for measuring the concentration of glimepiride in plasma.

The invention discloses a method for measuring cefadroxil concentration in plasma through hygroplasm combination. A hygroplasm combination system is adopted for measurement. The method comprises the steps that firstly, a to-be-measured sample is taken, a certain quantity of mixed organic solvent is added for conducting extraction twice, and after pretreatment, through chromatographic column separation, a mass spectrometry detector is used for detection. The method is quick to use, accurate, high in sensitivity and easy and convenient to operate, and the basis is provided for plasma concentration measurement of cefadroxil. The linear range of a plasma standard curve is within 0.1-60 mug / mL, the within-run precision and between-run precision RSD are smaller than + / -15%, and the method is suitable for measurement of cefadroxil concentration in plasma.

The invention discloses a method for determining the concentration of serodosin and KMD-3213G in plasma by using liquid chromatography-mass spectrometry. The concentration of serodosin and KMD-3213G in the plasma is determined by using a liquid chromatography-mass spectrometry system; taking a sample to be tested first, and adding a certain amount of mixed organic solvent for extraction twice; after pretreatment, performing chromatographic column separation, and then detecting by using a mass spectrometry detector. The method for determining the concentration of serodosin and KMD-3213G in theplasma by using the liquid chromatography-mass spectrometry disclosed by the invention has the advantages of rapid, accurate, high sensitivity and simple operation, and provides a basis for determining the blood concentration of serodosin and KMD-3213G. According to the plasma standard curve of the method, the quantitative range of serodosin is 0.2-60 ng / mL, the quantitative range of KMD-3213G is0.2-40 ng / mL, and the intra-assay and inter-assay precisions RSDs are less than + / -15%, which is suitable for determining the concentration of serodosin and KMD-3213G in the plasma.

The invention discloses a method for determining the concentration of azithromycin in plasma by liquid chromatography-mass spectrometry, which adopts a liquid chromatography-mass spectrometry system for determination and comprises the steps of taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction, separating by a chromatographic column after pretreatment,and detecting by a mass spectrum detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the plasma concentration of azithromycin. According to the method, the linear range of a plasma standard curve is 1-500ng / mL, the intra-batch precision RSD and the inter-batch precision RSD are both less than + / -15%, and the method is suitable for determining the concentration of azithromycin in plasma.

The invention discloses a method for detecting the concentration of hydrocortisone in plasma by liquid chromatography-mass spectrometry. The method adopts a liquid chromatography-mass spectrometry system for determination and comprises the following steps: firstly taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction, pretreating, separating by a chromatographic column, and detecting by a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for determining the blood concentration of the hydrocortisone; and the linear range of the plasma standard curve of the method is 0.01-3 ng / mL, the intra-batch and inter-batch precision RSD is less than + / -15%, and the method is suitable for measuring the concentration of the hydrocortisone in the plasma.

The invention discloses a method for determining concentration of dexamethason in plasma by liquid chromatography mass spectrometry. A liquid chromatography mass spectrometry system is used for determining. A sample to be determined is added with a certain amount of mixed organic solvent to extract twice, is separated by a chromatographic column after pretreatment, and is detected by a mass spectrometer. The method is rapid, accurate, high in sensitivity, and simple and convenient to operate. The method provides a basis for the blood drug concentration determination of dexamethason. The linearrange of a plasma standard curve in the method is 0.1 to 20 ng / mL. The intra-batch and inter-batch precision RSD are less than + / -15%. The method is suitable for determining the concentration of dexamethason in the plasma.

The invention discloses a method for determining the concentration of ibuprofen in blood plasma by liquid chromatography-mass spectrometry, which adopts a liquid chromatography-mass spectrometry system for determination, and comprises the following steps: taking a sample to be determined, adding a certain amount of mixed organic solvent for extraction and pretreatment, performing separating by using a chromatographic column, and performing detecting by a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the blood concentration of ibuprofen; according to the method, the linear range of the plasma standard curve is 0.1-40 mu g / mL, the intra-batch precision RSD andthe inter-batch precision RSD are both smaller than + / -15%, and the method is suitable for measuring the concentration of ibuprofen in plasma.

The invention provides a method for determining concentrations of prednisone, prednisone acetate and active metabolite prednisolone thereof in blood plasma by means of liquid chromatography-mass spectrometry. The method comprises the steps of: (1) pretreating a blood plasma sample; (2) detecting the blood plasma sample by adopting liquid chromatography-mass spectrometry; (3) preparing a standard curve; and (4) determining the concentrations of prednisone, prednisone acetate and active metabolite prednisolone thereof in the blood plasma. The pretreatment method disclosed by the invention is simple, high in specificity and high in sensitivity, and the method is rapid, precise, high in sensitivity, simple in operation and suitable for clinical application of medicines.

The invention discloses a method for measuring cefalexin concentration in plasma through hygroplasm combination. A hygroplasm combination system is adopted for measurement. The method comprises the steps that firstly, a to-be-measured sample is taken, a certain quantity of mixed organic solvent is added for conducting extraction twice, and after pretreatment, through chromatographic column separation, a mass spectrometry detector is used for detection. The method is quick to use, accurate, high in sensitivity and easy and convenient to operate, and the basis is provided for plasma concentration measurement of cefalexin. The linear range of a plasma standard curve is within 0.1-50 mug / mL, the within-run precision and between-run precision RSD are smaller than + / -15%, and the method is suitable for measurement of cefalexin concentration in plasma.

The invention discloses a method for determining the concentration of pregabalin in plasma by liquid chromatography-mass spectrometry, which adopts a liquid chromatography-mass spectrometry system fordetermination and comprises the steps of taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction, separating by using a chromatographic column after pretreatment, and detecting by using a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the plasma concentration of pregabalin; and the linear range of a plasma standard curve of the method is 0.05-15[mu]g / mL, the intra-batch precision RSD and the inter-batch precision RSD are both less than + / -15%, and the method is suitable for measuring the concentration of pregabalin in plasma.

The invention discloses a method for determining the concentration of chartreusin in blood plasma through liquid chromatography-tandem mass spectrometry. The method comprises the following steps: separating chartreusin from a blood plasma sample by liquid chromatography, then establishing a standard curve by taking the concentration of chartreusin in a calibration standard sample as an X axis andthe peak area ratio of chartreusin to an internal standard substance in the calibration standard sample as a Y axis by utilizing a mass spectrum internal standard quantitative method, and calculatingthe concentration of chartreusin in the blood plasma. The method has the following advantages of: (1) strong specificity: the retention time of the chartreusin and the internal standard naringenin isabout 0.6min, and endogenous substances do not interfere with the determination of the chartreusin and the internal standard naringenin; (2) short analysis time: the detection time of each sample is 1min; (3) high sensitivity: the minimum quantification limit is 1ng.ML<-1>; and (4) the linear range of the blood plasma standard curve of the method is 1-1000ng.ML<-1>, and the intra-batch precision CV and the inter-batch precision CV are both less than 10%.

The invention discloses a method for determining concentration of licorice glycoside C2 in blood plasma. A liquid chromatography-mass spectrometry system is adopted for determination, firstly, a to-be-determined sample is taken, a certain quantity of organic solvent protein precipitation solutions are added, a chromatographic column is used for separation after pretreatment, and a mass spectrometry detector is used for detection. The method is rapid, accurate, high in sensitivity, simple and convenient to operate and suitable for determining the concentration of licorice glycoside C2 in the blood plasma.

The invention discloses a method for determining the concentration of imidafenacin in blood plasma by liquid chromatography-mass spectrometry. The method adopts a liquid chromatography-mass spectrometry system for determination and comprises the following steps: taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction and pretreatment, separating by using a chromatographic column, and detecting by using a mass spectrum detector. The method is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the blood concentration of imidafenacin; the linear range of the plasma standard curve of the method is 0.01-2ng / mL, the intra-batch precision RSD and the inter-batch precision RSD are both smaller than + / -15%, and the method is suitable for measuring the concentration of imidafenacin in blood plasma.

The invention discloses a method for measuring the concentration of felodipine in plasma by liquid chromatography-mass spectrometry. The method adopts a liquid chromatography-mass spectrometry system for measurement, and comprises the following steps: firstly taking a sample to be detected, adding a certain amount of mixed organic solvent for extraction and pretreatment, separating by a chromatographic column, and detecting by a mass spectrometry detector. The method disclosed by the invention is rapid, accurate, high in sensitivity and simple and convenient to operate, and provides a basis for measuring the blood concentration of felodipine; and the linear range of the plasma standard curve of the method is 0.02-4 ng / mL, the intra-batch and inter-batch precision RSD is less than + / -15%, and the method is suitable for measuring the concentration of felodipine in the plasma.

The invention discloses a method for determining concentration of robustaside B in blood plasma. A liquid chromatography-mass spectrometry system is adopted for determination, firstly, a to-be-determined sample is taken, a certain quantity of organic solvent protein precipitation solutions are added, a chromatographic column is used for separation after pretreatment, and a mass spectrometry detector is used for detection. The method is rapid, accurate, high in sensitivity, simple and convenient to operate and suitable for determining the concentration of robustaside B in the blood plasma.